Number of pay-for-delay deals remains low, says FTC
07-12-2020
Judge gives initial approval to Actavis $20m antitrust deal
15-09-2020
rafapress / Shutterstock.com
New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder (ADHD) drug Quillivant XR (methylphenidate).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Tris, Actavis, ADHD, generics, Ritalin, methylphenidate, Quillivant XR, Federal Circuit
